摘要
目的分析急性缺血性脑卒中(AIS)患者在常规治疗的基础上联合使用疏血通注射液(SXTI)的治疗效果。方法随机抽取2022年3月至2023年3月在周口市中心医院接受治疗的100例AIS患者,按照不同治疗方案分组,A组(48例,常规治疗)、B组(52例,在A组基础上加用SXTI),比较两组血脂指标,炎性因子指标、颈动脉内中膜厚度(CIMT)、斑块面积,美国国立卫生研究院卒中量表(NIHSS)评分,日常生活活动能力(ADL)评分,Fugl-Meyer运动功能评定量表(FMA)评分,治疗有效率、不良反应发生率,健康调查简表(SF-36)评分。结果治疗前,两组血脂水平比较,差异无统计学意义(P>0.05);治疗后,两组TC、TG、LDL-C、LP水平均低于治疗前,HDL-C水平高于治疗前,且B组TC、TG、LDL-C、LP水平均低于A组,HDL-C水平高于A组,差异具有统计学意义(P<0.05)。治疗前,两组炎性因子指标、CIMT、斑块面积比较,差异无统计学意义(P>0.05);治疗后,两组hs-CRP、IL-8、TNF-α、CIMT、斑块面积均低于治疗前,且B组hs-CRP、IL-8、TNF-α、CIMT、斑块面积均低于A组,差异有统计学意义(P<0.05)。治疗前,两组NIHSS各项评分比较,差异无统计学意义(P>0.05),治疗后,两组NIHSS各项评分均低于治疗前,且B组NIHSS各项评分均低于A组,差异具有统计学意义(P<0.05)。治疗前,两组ADL评分比较,差异无统计学意义(P>0.05),治疗后,两组ADL评分高于治疗前,且B组ADL评分高于A组,差异具有统计学意义(P<0.05)。治疗前,两组FMA各项评分比较,差异无统计学意义(P>0.05),治疗后,两组FMA各项评分均高于治疗前,且B组FMA各项评分均高于A组,差异具有统计学意义(P<0.05)。B组治疗有效率高于A组,差异具有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。治疗前,两组SF-36各项评分比较,差异无统计学意义(P>0.05),治疗后,两组SF-36各项评分均高于治疗前,且B组SF-36各项评分均高于A组,差异具有统计学意义(P<0.05)。结论AIS患者在常规治疗的基础上联合使用SXTI,可改善患者血脂水平、炎性因子指标,临床疗效较为理想,提升患者生活质量,且不会额外增加不良反应。
Objective To analyze the therapeutic effect of combining Shuxuetong Injection(SXTI)with conventional treatment in patients with acute ischemic stroke(AIS).Methods A total of 100 AIS patients treated at Zhoukou Central Hospital from March 2022 to March 2023 were randomly selected and divided into two groups based on different treatment protocols:Group A(48 cases,conventional treatment)and Group B(52 cases,conventional treatment combined with SXTI).Blood lipid indicators,inflammatory factors,carotid intima-media thickness(CIMT),plaque area,National Institutes of Health Stroke Scale(NIHSS)scores,activities of daily living(ADL)scores,Fugl-Meyer motor function assessment(FMA)scores,treatment efficacy,incidence of adverse reactions,and Short Form Health Survey(SF-36)scores were compared between the two groups.Results Before treatment,there were no statistically significant differences in blood lipid levels between the two groups(P>0.05).After treatment,total cholesterol(TC),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C),and lipoprotein(a)(LP(a))levels were lower,and high-density lipoprotein cholesterol(HDL-C)levels were higher in both groups compared to before treatment.Group B had significantly lower TC,TG,LDL-C,and LP(a)levels and higher HDL-C levels than Group A(P<0.05).Before treatment,there were no significant differences in inflammatory factors,CIMT,and plaque area between the two groups(P>0.05).After treatment,high-sensitivity C-reactive protein(hs-CRP),interleukin-8(IL-8),tumor necrosis factor-alpha(TNF-α),CIMT,and plaque area were lower in both groups compared to before treatment,with Group B showing significantly lower levels than Group A(P<0.05).Before treatment,there were no significant differences in NIHSS scores between the two groups(P>0.05).After treatment,NIHSS scores were lower in both groups compared to before treatment,with Group B showing significantly lower scores than Group A(P<0.05).Before treatment,there were no significant differences in ADL scores between the two groups(P>0.05).After treatment,ADL scores were higher in both groups compared to before treatment,with Group B showing significantly higher scores than Group A(P<0.05).Before treatment,there were no significant differences in FMA scores between the two groups(P>0.05).After treatment,FMA scores were higher in both groups compared to before treatment,with Group B showing significantly higher scores than Group A(P<0.05).The treatment efficacy rate in Group B was higher than that in Group A,with statistically significant differences(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Before treatment,there were no significant differences in SF-36 scores between the two groups(P>0.05).After treatment,SF-36 scores were higher in both groups compared to before treatment,with Group B showing significantly higher scores than Group A(P<0.05).Conclusion Combining SXTI with conventional treatment in AIS patients can improve blood lipid levels,inflammatory factors,and clinical efficacy,enhance the quality of life,and does not increase adverse reactions.
作者
刘亚首
夏磊
LIU Yashou;XIA Lei(Second Neurology Ward,Zhoukou Central Hospital,Zhoukou Henan 466000,China)
出处
《临床研究》
2024年第11期102-106,共5页
Clinical Research
作者简介
刘亚首,男,主治医师,硕士研究生。研究方向:脑血管疾病,脊髓疾病,中枢神经系统感染性疾病,癫痫,痴呆,重症肌无力等;通讯作者:夏磊,主任医师,tzbxxx@163.com。
